CompoAtlas

Coenzyme Q10

Food supplement declared in France, decision dated 26 October 2026

Coenzyme Q10 (Gerson) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition.

Brand
Gerson
Food business operator placing the product on the market
GERSON
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
1 capsule
Directions for use
Prendre 1 capsule par jour, de préférence au cours d’un repas, avec un verre d’eau. Ne pas dépasser la dose journalière recommandée.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Breastfeeding women, Pregnant women, Taking anticoagulants, Children (under 6)
Objectives stated by the manufacturer (these are not authorised claims)
Antioxidant
Flavourings
/

Declaration 380410, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Other active ingredients

NamePer day
Ubiquinonenot declared

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Tenir hors de portée des jeunes enfants. Déconseillé aux enfants de moins de 6 ans. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Les personnes sous traitement anticoagulant doivent demander l’avis d’un professionnel de santé avant utilisation. Conserver dans un endroit frais et sec.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

This name is used by more than 10 declarations from different companies, so it does not identify one product. See every declaration with this name.

Brand : Gerson

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.